TABLE 2.
Immunological, virological, and clinical findings for the 7 patients with CMV infection in the prophylaxis strategy groupa
| QFN-CMV result (time point following suspension of CMV prophylaxis; T1) | QFN-CMV result (time point following first CMV DNAemia; T3) | First CMV DNAemia (no. of days post-Tx) | Peak CMV DNAemia in IU/ml WB (no. of days post-Tx) | Antiviral therapyb | CMV disease |
|---|---|---|---|---|---|
| Indeterminate | Positive | 86 | 1,058 (107) | No | No |
| Indeterminate | Positive | 75 | 966 (110) | No | No |
| Negative | Positive | 53 | 3,723 (104) | No | No |
| Indeterminate | Indeterminate | 84 | 10,394 (110) | Yes | No |
| Indeterminate | Indeterminate | 88 | 7,818 (119) | Yes | Syndrome |
| Indeterminate | Indeterminate | 87 | 16,124 (118) | Yes | No |
| Indeterminate | Indeterminate | 86 | 376,971 (120) | Yes | No |
a
Pt, patient; Tx, transplant; WB, whole blood; T1, 1 month posttransplant; T3, 3 months posttransplant.
b
Valganciclovir at 900 mg twice daily (renal function adjusted) until at least two consecutive whole-blood samples gave CMV DNA-negative results.